赤芝酸LM1 | 364622-33-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 赤芝酸LM1
• 英文名称: Lucidenic acid N
• 英文别名: (4R)-4-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• CAS: 364622-33-3
• 化学式: C₂₇H₄₀O₆
• 分子量: 460.6
• InChiKey: YBGBNHHXOJXFNM-UQCMLMITSA-N

物化性质

• 熔点：
  202-204 °C
• 沸点：
  640.7±55.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

制备方法与用途

生物活性方面，卢臣酸LM1是从灵芝中分离出的一种天然萜类化合物。

文献信息

• Compound, composition and method for treating and/or ameoliorating kidney disease
  申请人：Trineo Biotechnology Co. Ltd

  公开号：EP2955191A1

  公开（公告）日：2015-12-16

  Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E2 (LAE2), lucidenic acid A (LAA), and lucidenic acid D2 (LAD2).

  本文公开了用于治疗或预防患有或易患肾病的受试者的组合物和方法。该方法包括以下步骤：向受试者施用剂量约为 1 至 10 mg/Kg 的式 (I) 化合物，以改善受试者的肾小球滤过率 (GFR)，与治疗前相比至少提高 4 倍、 该方法进一步包括向受试者施用有效量的葡糖酸C（LAC）、葡糖酸N（LAN）、葡糖酸E2（LAE2）、葡糖酸A（LAA）和葡糖酸D2（LAD2）的步骤。
• COMPOUND, COMPOSITION AND METHOD FOR TREATING AND/OR AMEOLIORATING KIDNEY DISEASE
  申请人：Trineo Biotechnology Co. LTD.

  公开号：US20150353595A1

  公开（公告）日：2015-12-10

  Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E 2 (LAE 2 ), lucidenic acid A (LAA), and lucidenic acid D 2 (LAD 2 ).
• US9512168B2
  申请人：——

  公开号：US9512168B2

  公开（公告）日：2016-12-06